DISCLOSURE DIGEST
US insider purchases disclosed in week 2026-W33
2026-08-10 to 2026-08-16. 421 purchase disclosures at 208 companies by 376 buyers; reported value $1.2bn.
- purchase disclosures
- 421
- companies
- 208
- buyers
- 376
- reported value
- $1.2bn
Largest reported purchases by company
| Company | Ticker | Buyers | Disclosures | Reported value |
|---|---|---|---|---|
| REPUBLIC SERVICES, INC. | RSG | 2 | 4 | $373.0M |
| Braveheart Bio, Inc. | BRVE | 8 | 8 | $218.9M |
| Audax Private Credit Fund, LLC | NONE | 7 | 7 | $101.8M |
| Attovia Therapeutics, Inc. | ATTO | 10 | 10 | $99.1M |
| BlossomHill Therapeutics, Inc. | BLSM | 12 | 12 | $60.2M |
| 51Talk Online Education Group | COE | 1 | 3 | $33.3M |
| QVC Group, Inc. | QVCG | 3 | 3 | $30.0M |
| Pinnacle Acquisition Corp | PNAQ | 6 | 6 | $29.8M |
| West Bay BDC LLC | NONE | 1 | 1 | $27.0M |
| Crescent Private Credit Income Corp | 5 | 5 | $17.8M | |
| Latigo Biotherapeutics, Inc. | LTGO | 7 | 7 | $17.6M |
| Liberty Capital Corp/NV | GLIBK | 1 | 1 | $13.6M |
| NATURES SUNSHINE PRODUCTS INC | NATR | 5 | 5 | $11.6M |
| ProFrac Holding Corp. | ACDC | 4 | 4 | $11.3M |
| HPS Real Assets Lending Co LP | NONE | 4 | 4 | $11.0M |
| INTEL CORP | INTC | 1 | 1 | $10.0M |
| Empery Digital Inc. | EMPD | 2 | 2 | $8.1M |
| American Assets Trust, Inc. | AAT | 1 | 2 | $7.8M |
| Borr Drilling Ltd | BORR | 2 | 2 | $6.5M |
| TXO Partners, L.P. | TXO | 1 | 2 | $5.6M |
| Privacore VPC Asset Backed Credit Fund | NONE | 1 | 1 | $5.0M |
| Outlook Therapeutics, Inc. | OTLK | 2 | 2 | $5.0M |
| Liberty Latin America Ltd. | LILA | 2 | 3 | $3.7M |
| Aptiv PLC | APTV | 2 | 2 | $3.1M |
| Chiron Real Estate Inc. | XRN | 3 | 6 | $2.5M |
Companies with two or more buyers
| Company | Ticker | Buyers | Disclosures | Reported value |
|---|---|---|---|---|
| TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD | TSM | 30 | 30 | $118.9k |
| BlossomHill Therapeutics, Inc. | BLSM | 12 | 12 | $60.2M |
| Attovia Therapeutics, Inc. | ATTO | 10 | 10 | $99.1M |
| Braveheart Bio, Inc. | BRVE | 8 | 8 | $218.9M |
| Audax Private Credit Fund, LLC | NONE | 7 | 7 | $101.8M |
| Latigo Biotherapeutics, Inc. | LTGO | 7 | 7 | $17.6M |
| Chemours Co | CC | 7 | 7 | $488.6k |
| Pinnacle Acquisition Corp | PNAQ | 6 | 6 | $29.8M |
| Crescent Private Credit Income Corp | 5 | 5 | $17.8M | |
| NATURES SUNSHINE PRODUCTS INC | NATR | 5 | 5 | $11.6M |
| Amrize Ltd | AMRZ | 5 | 5 | $838.9k |
| Hepion Pharmaceuticals, Inc. | HEPA | 5 | 5 | $825.0k |
| KEMPER Corp | KMPR | 5 | 5 | $367.9k |
| FEMASYS INC | FEMY | 5 | 5 | $134.0k |
| ProFrac Holding Corp. | ACDC | 4 | 4 | $11.3M |
| HPS Real Assets Lending Co LP | NONE | 4 | 4 | $11.0M |
| Compass Diversified Holdings | CODI | 4 | 4 | $1.5M |
| Embecta Corp. | EMBC | 4 | 4 | $557.9k |
| JEWETT CAMERON TRADING CO LTD | JCTC | 4 | 4 | $139.1k |
| BANK OF THE JAMES FINANCIAL GROUP INC | BOTJ | 4 | 4 | $34.7k |
| QVC Group, Inc. | QVCG | 3 | 3 | $30.0M |
| Chiron Real Estate Inc. | XRN | 3 | 6 | $2.5M |
| Infleqtion, Inc. | INFQ | 3 | 3 | $1.9M |
| CROSS TIMBERS ROYALTY TRUST | CRT | 3 | 3 | $783.6k |
| SOLITRON DEVICES INC | SODI | 3 | 3 | $684.0k |
By buyer role
| Buyer role | companies | Disclosures | Reported value |
|---|---|---|---|
| 10% Owner | 38 | 93 | $720.3M |
| Director | 110 | 147 | $272.1M |
| Other | 6 | 19 | $85.0M |
| Chief Executive Officer | 57 | 68 | $80.3M |
| Executive Chairman | 4 | 6 | $9.0M |
| Chief Financial Officer | 15 | 15 | $2.2M |
| Officer | 10 | 13 | $1.3M |
| See Remarks | 5 | 7 | $711.7k |
| COO | 1 | 1 | $495.9k |
| CLO, CCO, CAO & Corp Sec | 1 | 1 | $197.8k |
| VP, CAO & Assistant Treasurer | 1 | 1 | $150.6k |
| SVP, Treasury, Tax & CAO | 1 | 1 | $107.5k |
| Pres, Pharm Svc&Prod Mgmt, CLO | 1 | 1 | $99.8k |
| SVP - Acetyls | 1 | 1 | $98.0k |
| President | 5 | 5 | $88.4k |
| General Counsel | 1 | 1 | $74.7k |
| VP | 1 | 16 | $55.3k |
| General Counsel/Secretary | 1 | 1 | $53.3k |
| Treasurer | 1 | 1 | $53.3k |
| EVP, Reservoir Engineering | 1 | 1 | $43.3k |
| SVP & GC | 1 | 1 | $27.4k |
| EVP, Sec. & General Counsel | 1 | 1 | $26.5k |
| SEE REMARKS | 1 | 1 | $25.7k |
| Chief Actuary | 1 | 1 | $20.6k |
| SVP | 1 | 5 | $20.3k |
| EVP and Co-COO | 1 | 2 | $10.6k |
| Chief Clinical-Medical Affairs | 1 | 1 | $10.0k |
| SVP and Deputy Co-COO | 1 | 2 | $9.2k |
| VP,Treasurer, Asst. Corp. Sec. | 1 | 1 | $5.8k |
| SVP and GC | 1 | 1 | $4.2k |
| VP and CIO | 1 | 1 | $3.6k |
| Controller | 1 | 1 | $2.4k |
| EVP/CRDEO | 1 | 1 | $1.3k |
| Secretary and CCO | 1 | 1 | $1.0k |
| EXEC. CHAIR & PRINCIPAL OFF | 1 | 2 | $861 |
Purchases are Form 4 open-market purchases (code P) of qualifying equity as classified by the site's US screening rules; grants, option exercises, gifts and derivatives are excluded. Values are as reported, in USD. No score or rank is used on this page.